0001564590-23-001667.txt : 20230522 0001564590-23-001667.hdr.sgml : 20230522 20230209160558 ACCESSION NUMBER: 0001564590-23-001667 CONFORMED SUBMISSION TYPE: CORRESP PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20230209 FILER: COMPANY DATA: COMPANY CONFORMED NAME: MAIA Biotechnology, Inc. CENTRAL INDEX KEY: 0001878313 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: CORRESP BUSINESS ADDRESS: STREET 1: 444 WEST LAKE STREET, SUITE 1700 CITY: CHICAGO STATE: IL ZIP: 60606 BUSINESS PHONE: 312-416-8592 MAIL ADDRESS: STREET 1: 444 WEST LAKE STREET, SUITE 1700 CITY: CHICAGO STATE: IL ZIP: 60606 CORRESP 1 filename1.htm maia-corresp.htm

 

MAIA Biotechnology, Inc.

4444 West Lake Street, Suite 1700

Chicago, IL 60606

 

 

February 9, 2023

 

VIA EDGAR & TELECOPY

 

U.S. Securities and Exchange Commission

Division of Corporation Finance

Office of Life Sciences

Washington, D.C. 20549

Attention: Jimmy McNamara 

 

RE:

MAIA Biotechnology, Inc. (the “Company”)

 

Registration Statement on Form S-1 (File No. 333-269606) (the “Registration Statement”)

Request for Acceleration of Effective Date

 

Ladies and Gentlemen:

 

In accordance with Rule 461 under the Securities Act of 1933, as amended (the “Act”), the Company requests that the Securities and Exchange Commission (the “Commission”) take appropriate action to cause the Registration Statement to become effective on February 13, 2023, at 5:00 p.m., Eastern Time, or as soon as practicable thereafter, or at such later time as the Company or its counsel may request via telephone call to the staff. In making this acceleration request, the Company acknowledges that it is aware of its obligations under the Act.

 

 

Very truly yours,

MAIA Biotechnology, Inc.

 

 

 

By: 

/s/ Vlad Vitoc

 

 

Name: 

Vlad Vitoc

 

 

Title:

Chief Executive Officer

 

 

 

cc:

Angela Dowd, Esq., Loeb & Loeb LLP